Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -22.69
- Piotroski Score 3.00
- Grade Buy
- Symbol (ATRA)
- Company Atara Biotherapeutics, Inc.
- Price $11.35
- Changes Percentage (-5.43%)
- Change -$0.65
- Day Low $10.81
- Day High $12.20
- Year High $39.50
Atara Biotherapeutics, Inc., an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as hematologic and solid tumors, including nasopharyngeal carcinoma. The company is also developing next-generation CAR T immunotherapies for patients with hematologic malignancies and solid tumors, including ATA2271 and ATA3271 for mesothelin; and ATA2431 and ATA3219 for B-cell malignancies, as well as ATA188 for the treatment of multiple sclerosis. In addition, it develops ATA368 program for patients with human papillomavirus associated cancers. Atara Biotherapeutics, Inc. has a license agreement with Memorial Sloan Kettering Cancer Center; license, and research and development collaboration agreement with QIMR Berghofer Medical Research Institute; and strategic collaboration with H. Lee Moffitt Cancer Center, as well as Bayer AG for mesothelin-targeted CAR T-cell therapies for solid tumors. The company was incorporated in 2012 and is headquartered in South San Francisco, California.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 11/12/2024
- Fiscal Year End N/A
- Average Stock Price Target $10.00
- High Stock Price Target $18.00
- Low Stock Price Target $3.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$2.12
- Trailing P/E Ratio -0.25
- Forward P/E Ratio -0.25
- P/E Growth -0.25
- Net Income $-276,126,000
Income Statement
Quarterly
Annual
Latest News of ATRA
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Dynatrace, Inc. Just Recorded A 8.8% EPS Beat: Here's What Analysts Are Forecasting Next
Dynatrace, Inc. recently reported strong quarterly results, surpassing revenue expectations by 2.9%. Analysts predict a 7% revenue increase in 2025, but a 15% decline in EPS. Despite this, the consens...
By Yahoo! Finance | 1 week ago -
'Leave your ego at the door': from Thriller to Sinatra, Quincy Jones collaborators tell the stories behind his songs
Artists who collaborated with Quincy Jones praise his talent, kindness, and passion for music. Jones, a legendary musician and producer, worked with icons like Michael Jackson and Frank Sinatra. His w...
By The Guardian | 1 week ago -
PIC completes Atradius UK Pension Scheme deal
Pension Insurance Corporation (PIC) secures £190m buy-in for Atradius UK Pension Scheme, safeguarding members' benefits. The deal covers deferred, pensioner, and active members, ensuring financial se...
By Yahoo! Finance | 1 week ago
